Brief: Ivonescimab Meets Overall Survival Key Secondary Endpoint In Interim Analysis Of Phase Iii Harmoni-2 Study, Demonstrating Statistically Significant And Clinically Meaningful Benefit Versus Pembrolizumab In First-Line Pd-L1-Positive Nsclc
02/09/2026 22:01
BRIEF-Ivonescimab Meets Overall Survival Key Secondary Endpoint In Interim Analysis Of Phase Iii Harmoni-2 Study, Demonstrating Statistically Significant And Clinically Meaningful Benefit Versus Pembrolizumab In First-Line Pd-L1-Positive Nsclc Sept 2 (Reuters) - Akeso Inc 9926.HK:
IVONESCIMAB MEETS OVERALL SURVIVAL KEY SECONDARY ENDPOINT IN INTERIM ANALYSIS OF PHASE III HARMONI-2 STUDY, DEMONSTRATING STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL BENEFIT VERSUS PEMBROLIZUMAB IN FIRST-LINE PD-L1-POSITIVE NSCLC
AKESO - IVONESCIMAB DEMONSTRATES STATISTICALLY SIGNIFICANT IMPROVEMENT OVER PEMBROLIZUMAB
Source text: ID:nPn35Dfb2a
Further company coverage: 9926.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals